SG149081A1 - Treatment of aromatase inhibitor therapy-related osteoporosis - Google Patents

Treatment of aromatase inhibitor therapy-related osteoporosis

Info

Publication number
SG149081A1
SG149081A1 SG200900062-1A SG2009000621A SG149081A1 SG 149081 A1 SG149081 A1 SG 149081A1 SG 2009000621 A SG2009000621 A SG 2009000621A SG 149081 A1 SG149081 A1 SG 149081A1
Authority
SG
Singapore
Prior art keywords
treatment
aromatase inhibitor
inhibitor therapy
related osteoporosis
osteoporosis
Prior art date
Application number
SG200900062-1A
Other languages
English (en)
Inventor
Simon N Jenkins
Barry S Komm
Pol Boudes
Philip Frost
Matthew L Sherman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG149081A1 publication Critical patent/SG149081A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
SG200900062-1A 2004-01-13 2005-01-11 Treatment of aromatase inhibitor therapy-related osteoporosis SG149081A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53603504P 2004-01-13 2004-01-13

Publications (1)

Publication Number Publication Date
SG149081A1 true SG149081A1 (en) 2009-01-29

Family

ID=34806981

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200900062-1A SG149081A1 (en) 2004-01-13 2005-01-11 Treatment of aromatase inhibitor therapy-related osteoporosis

Country Status (19)

Country Link
US (1) US20050272717A1 (fr)
EP (1) EP1703910A2 (fr)
JP (1) JP2007517899A (fr)
KR (1) KR20060127875A (fr)
CN (1) CN1929835A (fr)
AR (1) AR048394A1 (fr)
AU (1) AU2005206137A1 (fr)
BR (1) BRPI0506774A (fr)
CA (1) CA2552725A1 (fr)
CR (1) CR8495A (fr)
EC (1) ECSP066699A (fr)
IL (1) IL176628A0 (fr)
NO (1) NO20063448L (fr)
PA (1) PA8621401A1 (fr)
RU (1) RU2006123939A (fr)
SG (1) SG149081A1 (fr)
TW (1) TW200526206A (fr)
UA (1) UA84046C2 (fr)
WO (1) WO2005070434A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114702A2 (fr) * 2005-04-25 2006-11-02 Pfizer Products Inc. Compositions pharmaceutiques et methodes comprenant une combinaison d'un modulateur selectif du recepteur de l'oestrogene et d'un inhibiteur de l'aromatase
WO2007024961A2 (fr) * 2005-08-24 2007-03-01 Wyeth Preparations de bazedoxifene acetate
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
JP5449775B2 (ja) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
WO2013182169A1 (fr) * 2012-06-07 2013-12-12 Zentiva, K. S. Procédé de préparation d'une formulation d'acétate de bazédoxifène sans anti-oxydant et stable du point de vue polymorphe et chimique
CN103860496A (zh) * 2014-03-14 2014-06-18 王志刚 一种醋酸巴多昔芬分散片及其制备方法
US20160051565A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
CA2965372C (fr) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Procede de reduction de densite mammaire monographique et/ou de risque de cancer du sein
CN104546794A (zh) * 2015-01-05 2015-04-29 万特制药(海南)有限公司 一种醋酸巴多昔芬胶囊及其制备方法
CN108472302A (zh) 2015-10-22 2018-08-31 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
EP3976048A4 (fr) 2019-06-03 2023-07-12 Havah Therapeutics Pty Ltd Formulations pharmaceutiques et systèmes pour l'administration d'un agent androgène et d'un inhibiteur de l'aromatase, et procédés d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (fr) * 2000-09-21 2004-03-03 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter l'ostéoarthrite
US20040192598A1 (en) * 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
EP1531807A4 (fr) * 2002-06-13 2007-10-31 Wyeth Corp Schemas therapeutiques du bazedoxifene

Also Published As

Publication number Publication date
CN1929835A (zh) 2007-03-14
TW200526206A (en) 2005-08-16
CR8495A (es) 2007-03-06
US20050272717A1 (en) 2005-12-08
KR20060127875A (ko) 2006-12-13
PA8621401A1 (es) 2006-07-03
WO2005070434A2 (fr) 2005-08-04
CA2552725A1 (fr) 2005-08-04
BRPI0506774A (pt) 2007-05-22
JP2007517899A (ja) 2007-07-05
AR048394A1 (es) 2006-04-26
NO20063448L (no) 2006-09-29
ECSP066699A (es) 2006-10-31
EP1703910A2 (fr) 2006-09-27
WO2005070434A3 (fr) 2006-06-08
AU2005206137A1 (en) 2005-08-04
RU2006123939A (ru) 2008-02-20
UA84046C2 (ru) 2008-09-10
IL176628A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
SG149081A1 (en) Treatment of aromatase inhibitor therapy-related osteoporosis
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
ZA200500323B (en) Use of lkb kinase inhibitors for the treatment of pain.
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MX2007009368A (es) Metodo para estimular la sintesis de colagena y/o expresion de factor de crecimiento de queratinocitos.
NO20075099L (no) Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
MXPA04006572A (es) Terapia de combinacion antivirica.
ATE492283T1 (de) Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen
IL177169A0 (en) Use of n- (2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
BRPI0514983A (pt) combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
IL188685A0 (en) Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
HU0001888D0 (en) 5ht1 receptor agonists and either cox-2 inhibitor or nsaid for the treatment of migraine
EP1603535A4 (fr) Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
ECSP055715A (es) Utilizacion de pirimetanilo en patogenos resistentes
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
EP1804805A4 (fr) Utilisation d'inhibiteurs d'aromatase pour le traitement de la grossesse ectopique
WO2008060837A3 (fr) Méthodes et compositions pour le traitement du cancer
PL370839A1 (en) Use of proton pump inhibitors for the treatment of airway disorders
PL370840A1 (en) Use of proton pump inhibitors for the treatment of noncardiac chest pain